IceCure Medical Completes 5-Year Follow-Up for ICESECRET Kidney Cancer Study; Final Analysis Expected Q2 2026

summarizeSummary

This filing marks a significant milestone for IceCure Medical, completing the long-term patient follow-up for its pivotal ICESECRET study. The ProSense system, already approved for kidney tumors in major markets, stands to gain substantial clinical validation from the upcoming final analysis. Previously released interim data showed a strong 88.7% recurrence-free rate, and the completion of the full five-year follow-up reinforces the potential for ProSense as a safe and effective minimally invasive treatment option, particularly for patients unsuitable for surgery. Investors should monitor for the final data publication in Q2 2026, which could further drive adoption and market penetration.

check_boxKey Events

• ICESECRET Study Follow-Up Completed

  IceCure Medical announced the successful completion of the five-year patient follow-up for its ICESECRET clinical trial, evaluating the ProSense system for small renal masses in kidney cancer patients.

• Final Analysis Expected Q2 2026

  The company anticipates the final data analysis and publication of results from the ICESECRET study in the second quarter of 2026.

• Strong Interim Data

  Previously released interim three-year data from the study demonstrated ProSense to be safe and effective, with an 88.7% recurrence-free rate in 111 eligible patients.

• Product Already Approved

  ProSense is currently approved for benign and malignant kidney tumors in the U.S., Europe, and other countries, positioning the company to leverage strong clinical data for market expansion.

auto_awesomeAnalysis

This filing marks a significant milestone for IceCure Medical, completing the long-term patient follow-up for its pivotal ICESECRET study. The ProSense system, already approved for kidney tumors in major markets, stands to gain substantial clinical validation from the upcoming final analysis. Previously released interim data showed a strong 88.7% recurrence-free rate, and the completion of the full five-year follow-up reinforces the potential for ProSense as a safe and effective minimally invasive treatment option, particularly for patients unsuitable for surgery. Investors should monitor for the final data publication in Q2 2026, which could further drive adoption and market penetration.